verbatim disclaimer

content/60.back-matter.md

@@ -15,7 +15,14 @@ All authors read and approved the final manuscript.
 
 We thank Hanna Schumacher, Daniel Dimitrov, Pau Badia i Mompel, and Aurelien Dugourd for feedback on the original draft of the manuscript and the software.
 
-This work was supported by funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965193 (SL) and 101057619 (JB), the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract No. 22.00115 (JB), award U54-AG075931 (QM) from the National Institutes of Health, award NSF1945971 (QM) from the National Science Foundation, and the Pelotonia Institute of Immuno-Oncology (PIIO).
+This work was supported by funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965193 (SL), award U54-AG075931 (QM) from the National Institutes of Health, award NSF1945971 (QM) from the National Science Foundation, and the Pelotonia Institute of Immuno-Oncology (PIIO).
+
+## Disclaimer
+
+This project is funded by the European Union under grant agreement No. 101057619.
+Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA).
+Neither the European Union nor the granting authority can be held responsible for them.
+This work was also partly supported by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract No. 22.00115.
 
 ## Conflict of Interest